Thomas Vanassche
A5025928709- Atrial Fibrillation Management and Outcomes
- Venous Thromboembolism Diagnosis and Management
- Cardiac Arrhythmias and Treatments
- Antiplatelet Therapy and Cardiovascular Diseases
- Antimicrobial Resistance in Staphylococcus
- Blood Pressure and Hypertension Studies
- Acute Ischemic Stroke Management
- Blood Coagulation and Thrombosis Mechanisms
- Infective Endocarditis Diagnosis and Management
- COVID-19 Clinical Research Studies
- Cardiovascular Health and Disease Prevention
- Streptococcal Infections and Treatments
- Central Venous Catheters and Hemodialysis
- Glaucoma and retinal disorders
- Heparin-Induced Thrombocytopenia and Thrombosis
- Acute Myocardial Infarction Research
- Platelet Disorders and Treatments
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Cardiac electrophysiology and arrhythmias
- Mechanical Circulatory Support Devices
- Biochemical and Structural Characterization
- Hemophilia Treatment and Research
- Cerebrovascular and Carotid Artery Diseases
- Hemodynamic Monitoring and Therapy
KU Leuven
2016-2025
Universitair Ziekenhuis Leuven
2017-2024
Hospital de Mataró
2024
Hôpital Edouard Herriot
2024
Hospital Universitario Virgen del Rocío
2023
University Medical Center of the Johannes Gutenberg University Mainz
2021-2022
Johannes Gutenberg University Mainz
2021-2022
Hospital Universitari Germans Trias i Pujol
2022
Universidad Católica San Antonio de Murcia
2020-2022
Ospedale Santa Maria della Misericordia di Rovigo
2022
CV Cardiovascular CYP Cytochrome P (CYP) Unfractionated heparin ULN Upper limit of normal VENTURE-AF Active-controlled multi-center study with blind-adjudication designed to evaluate the safety uninterrupted Rivaroxaban and vitamin K antagonists in subjects undergoing catheter ablation for non-valvular Atrial Fibrillation VHD Valvular heart disease VKA Vitamin antagonist VTE Venous thromboembolic event WOEST What is Optimal antiplatelet anticoagulant therapy patients oral anticoagulation...
Patients with atrial fibrillation (AF) who use a direct oral anticoagulant (DOAC) and request elective surgery or procedure present common clinical situation yet perioperative management is uncertain.To investigate the safety of standardized DOAC strategy.The Perioperative Anticoagulation Use for Surgery Evaluation (PAUSE) cohort study conducted at 23 centers in Canada, United States, Europe enrolled screened patients from August 1, 2014, through July 31, 2018. Participants (n = 3007) had...
AimsThe pattern of atrial fibrillation (AF) occurrence—paroxysmal, persistent, or permanent—is associated with progressive stages dysfunction and structural changes may therefore be progressively higher stroke risk. However, previous studies have not consistently shown AF to predict but been hampered by methodological shortcomings low power, variable event ascertainment, anticoagulant use.
Oral activated factor XI (FXIa) inhibitors may modulate coagulation to prevent thromboembolic events without substantially increasing bleeding. We explored the pharmacodynamics, safety, and efficacy of oral FXIa inhibitor asundexian for secondary prevention after acute myocardial infarction (MI).We randomized 1601 patients with recent MI 10, 20, or 50 mg placebo once daily 6 12 months in a double-blind, placebo-controlled, phase 2, dose-ranging trial. Patients were within 5 days their...
Background Recent evidence supports that most non-lacunar cryptogenic strokes are embolic. Accordingly, these have been designated as embolic of undetermined source (ESUS). Aims We undertook an international survey to characterize the frequency and clinical features ESUS patients across global regions. Methods Consecutive hospitalized for ischemic stroke were retrospectively surveyed from 19 research centers in different countries collect meeting criteria ESUS. Results Of 2144 with recent...
The pathogenesis of endocarditis is not well understood resulting in unsuccessful attempts at prevention. Clinical observations suggest that Staphylococcus aureus infects either damaged or inflamed heart valves. Using a newly developed mouse model, we therefore studied the initial adhesion S. both risk states.Using 3D confocal microscopy, examined fluorescent to murine aortic To mimic different states valves with surgically placed catheter simulated valve inflammation by local endothelium...
Background The perioperative management of patients who take a direct oral anticoagulant (DOAC) for atrial fibrillation and require treatment interruption an elective surgery/procedure is common clinical scenario which best practices are uncertain. Perioperative Anticoagulant Use Surgery Evaluation (PAUSE) study designed to address this unmet need. We discuss the rationale PAUSE design analysis plan as well supporting DOAC protocol. Methods prospective with three parallel cohorts, one each...